

OHE Luchtime Seminar

**Steven Pearson
Founder and President
Institute for Clinical and Economic Review (ICER)**

**“Early experience with HTA of gene therapies in the US:
Pricing and paying for cures”**

22nd October 2018 12:00-2:00pm

**Sir Alexander Fleming Room
Southside, 7th Floor, 105 Victoria Street, London SW1E 6QT**

A buffet lunch will be available from 12:00 noon.

The seminar will start promptly at 12:30 pm and finish promptly at 2:00 pm.

The time is rapidly approaching when health care funders and health care systems around the world must be able to manage a growing number of drugs offering potential cures for a wide range of illnesses. The innovation pipeline includes potential cures for haemophilia, sickle cell disease, and numerous other genetically-based conditions. Individually, each treatment will be extremely expensive, and in the aggregate their costs are projected to have a substantial impact on the affordability of health care. Stated frankly, health systems today are ill prepared to face the challenge of assessing and paying for the potential cures that will soon become available.

As the leading health technology assessment organization in the US, ICER has completed reviews of three gene therapies and is in the midst of a fourth review. Dr Steven Pearson, ICER's President, will discuss the distinctive challenges in analysing the clinical and cost-effectiveness of these therapies, and the lessons learned to date. As part of this discussion Dr Pearson will present the early outlines of options for new methods to calculate “value-based” prices for potential cures that offer magnitudes of health gains and future cost offsets that have never been generated by traditional treatments.

Steven D. Pearson, MD, MSc is the Founder and President of the Institute for Clinical and Economic Review (ICER), an independent health technology assessment organization based in the US. Prominent among its evidence reports are ICER reviews of new drugs that include full assessments of clinical and cost-effectiveness along with suggested “value-based price benchmarks” to guide price and coverage negotiation. Dr Pearson is a Lecturer in the Department of Population Medicine at Harvard Medical School and also serves as Visiting Scientist in the Department of Bioethics at the National Institutes of Health. His published work includes over 100 articles on quality of care, the role of evidence-based medicine within the health care system, and related clinical, ethical, and organizational policy challenges. His book, *No Margin, No Mission: Health Care Organizations and the Quest for Ethical Excellence*, was published by Oxford University Press.

If you would like to attend this seminar, please reply to ohgeneral@ohe.org. If you are unable to attend but think that a colleague might like to, please pass on this letter to them.



Adrian Towse (Director)